MOTS-c Before and After: What Changes, and When

MOTS-c Before and After: The Honest Version

Search this phrase and the results agree with each other to a suspicious degree. Energy in the first two weeks. Visceral fat and insulin sensitivity moving by week six. Visible body-composition change by week twelve. The reason the pages agree is not that they cite the same trial. It is that there is no trial to cite. As of September 2026, no completed study of injected MOTS-c Explore PeRxMOTS-cThe Mitochondrial PeptideView peptide in humans has reported a result, and the FDA evaluation prepared for its July 2026 advisory meeting found no clinical studies and no human exposure data for the peptide by any route. The timelines were written from user reports, one four-week study of a modified analog, and mice.

That does not make a MOTS-c before-and-after meaningless. It means the honest version has to be built from three piles: what patients typically report, what has actually been measured in people, and what you can measure in yourself. One fact shapes all three. MOTS-c is a signal the body sends itself after hard work; in a small group of healthy young men, a single workout raised it roughly twelve-fold in muscle and 1.6-fold in blood. Signals like that produce gradual, metabolic change, which is why the domains that move first are the ones you feel in a workout and read on a lab slip, and why a camera is the last instrument to notice anything. Mechanism and the dosage chart live in the MOTS-c guide Read nextMOTS-c Dosage Chart: Units, Protocols & EffectsMOTS-c is the 16-amino-acid mitochondrial peptide your body releases during exercise. This guide leads with what most readers came for: a real dosage chart with per-injection amounts, insulin syringe unit conversions, weekly totals, and cycle lengths. Then it covers the AMPK mechanism, the metformin comparison, the 2015 USC discovery story, and an honest read of the evidence.Read article , the graded evidence in MOTS-c benefits Read nextMOTS-c Benefits: What the Evidence SupportsAlmost every benefit attributed to MOTS-c traces back to a mouse, a cell culture, or a blood test measuring the peptide your own mitochondria already make. This page grades each claim by what was measured, what it was measured in, and whether anyone has given injected MOTS-c to a person and looked.Read article , and the risks in MOTS-c side effects Read nextMOTS-c Side Effects: What Is Known and What Is NotEvery MOTS-c side-effect list online shares one problem: no study of injected MOTS-c in people has ever reported results, so none of those lists has a number behind it. This page sorts the evidence into what was measured in humans (almost nothing, mostly on an analog), what FDA reviewers flagged in 2026, and what users report, with straight answers on blood sugar, cancer, and the heart.Read article . This page owns one question: what changes, in what order, and how you would know.

The Week-by-Week Timeline, Sourced

Here is the timeline most pages publish, with one change: each stage is labeled by where the claim comes from. A typical clinic cycle runs 8 to 12 weeks with two to five subcutaneous injections a week; your prescription and the concentration on your vial set the dose, and the dosage chart Read nextMOTS-c Dosage Chart: Units, Protocols & EffectsMOTS-c is the 16-amino-acid mitochondrial peptide your body releases during exercise. This guide leads with what most readers came for: a real dosage chart with per-injection amounts, insulin syringe unit conversions, weekly totals, and cycle lengths. Then it covers the AMPK mechanism, the metformin comparison, the 2015 USC discovery story, and an honest read of the evidence.Read article does the syringe math.

Weeks 1 to 2: The Placebo Window

Two things happen in the first fortnight, and only one is verifiable. The verifiable one is at the injection site: brief redness, a little soreness or a small bruise, usually gone within a day. The CB4211 program paused dosing in 2018 over bumps it called mild but unexpectedly persistent, so a firm lump that lingers deserves a photo and a message to your prescriber. Rotate sites from the first dose; the injection-site guide Read nextWhere to Inject MOTS-c: Sites, Rotation, TimingMOTS-c is a subcutaneous injection. The four standard sites work, but rotation, timing relative to exercise, and a few small technique details meaningfully change comfort and consistency. Here is the practical guide patients ask for after their first vial arrives.Read article covers how. The other thing is the feeling. People commonly report more energy within days, and it would be dishonest to pretend they do not. It would be equally dishonest to count it: starting a new injectable you paid for and read about is one of the most reliable ways to feel better for two weeks, and no study has separated that from the peptide. Write it down as a 1 to 10 rating each morning and draw no conclusions until the numbers below have had a chance to agree or disagree.

Weeks 3 to 6: Stamina and the First Numbers

If MOTS-c has a signature domain, it is the one the discovery research pointed at: physical capacity. In the 2021 Nature Communications study, mice given MOTS-c improved their treadmill running, and late-life treatment improved physical capacity in old animals. Mice are not people, but it is why the first thing worth watching is a training log rather than a mirror. What people typically report in weeks three to six is that a hard session no longer wrecks the next one. The trick is to make that testable: add a soreness note to the log, and pick one benchmark you can repeat identically every two weeks, a timed distance, a fixed circuit, a set at a fixed load to failure. If that number improves across a cycle while training and sleep stayed the same, that is a before-and-after.

The other number that can move in this window is glucose, the one place a human measurement exists. In the four-week Phase 1b stage of the CB4211 trial, 20 adults with obesity and fatty liver disease received 25 mg of the analog under the skin daily or placebo. Against placebo, glucose fell 6%, and the liver enzymes ALT and AST fell 21% and 28%. Two cautions: CB4211 was engineered to behave better as a drug than the natural peptide, so its result is a hint about MOTS-c rather than a finding about it, and 11 treated people over four weeks is a very small window. A fasting glucose at baseline and around week four is how you find out whether the hint applies to you.

Weeks 8 to 12: Waist, HbA1c, and the End of the Cycle

This is the stage every MOTS-c page describes most confidently and supports least. The body-composition story comes from mice: in the 2015 discovery paper, MOTS-c prevented diet-induced obesity and insulin resistance in animals on a high-fat diet without reducing how much they ate. The only human weight data, from the analog trial, was a trend toward lower weight that did not reach significance in four weeks. So the honest expectation at the end of a cycle is a small change in waist circumference at most, with training and nutrition doing the visible work. The lab that fits this window is HbA1c. It reflects roughly three months of average blood sugar, so a draw at baseline and again at the end of a 12-week cycle is the first single number that can summarize a full cycle, which is why the Phase 2a trial reads its endpoints at week 12. The point is to replace "I think it worked" with two numbers on a page that your physician interprets.

Then the cycle ends, and that matters more for this peptide than for most. There is no long-term human safety data on MOTS-c, and the FDA’s 2026 review flagged immunogenicity as never assessed, which is part of why clinics run 8 to 12 weeks and then break; the peptide cycling guide Read nextPeptide Cycling Chart: When to Pause Each ClassPeptide therapy is rarely meant to run forever. Some peptides need scheduled breaks to keep working. Others can be used continuously. The right cycle depends on the peptide class, your goals, and what is happening at the receptor level. Here is the practical guide to cycling, peptide by peptide.Read article covers the logic. The data you collected, brought to your provider, decides whether a second cycle makes sense.

What the Human Data Actually Shows

Because this page leans on a handful of studies, here they are with what each can support. Two papers carry the mechanism and the mouse results, and neither injected MOTS-c into a human.

Lee C, Zeng J, Drew BG, et al. "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance." Cell Metabolism, 2015. (Mouse and cell study; the discovery paper. Prevented diet-induced obesity and insulin resistance in mice without reducing food intake.) View study

Reynolds JC, Lai RW, Woodhead JST, et al. "MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis." Nature Communications, 2021. (Human exercise measurements in a small group of young men plus mouse treatment studies; the human part measured the body’s own MOTS-c, not an injection.) View study

The human injection data is the CB4211 program: a Phase 1a stage in healthy volunteers and the four-week Phase 1b stage above, 11 on 25 mg daily and 9 on placebo. The company reported the glucose and liver-enzyme reductions, a trend toward lower weight, no serious adverse events, and injection-site reactions as the only adverse event in more than 10% of treated subjects. The results came by press release in 2021 and were never published in a journal. One observational study explains why a MOTS-c blood test is not a useful before-and-after: plasma levels sat near 0.5 ng/mL in lean and obese adults alike, and nobody has established what an injected dose does to that number.

CohBar, Inc. "A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease." ClinicalTrials.gov identifier NCT03998514. Completed April 2021; topline results by company press release only, no results posted to the registry. View study

Cataldo LR, Fernández-Verdejo R, Santos JL, Galgani JE. "Plasma MOTS-c levels are associated with insulin sensitivity in lean but not in obese individuals." Journal of Investigative Medicine, 2018. (Observational; 10 lean and 10 obese adults; plasma MOTS-c about 0.5 ng/mL in both groups.) View study

Two more things belong in the record. A 2015 Aging Cell paper proposed that a MOTS-c gene variant common in Northeast Asian populations might be one factor behind Japanese longevity; it is a hypothesis paper by its own description, not evidence that injected MOTS-c extends life. And the first placebo-controlled trial of MOTS-c itself, MOTS-MET, began recruiting in February 2026: about 120 adults with prediabetes, a daily subcutaneous dose or placebo for 12 weeks, insulin sensitivity as the primary endpoint, primary completion estimated for February 2027. Until it reports, every human before-and-after for MOTS-c is a self-experiment, including yours.

Fuku N, Pareja-Galeano H, Zempo H, et al. "The mitochondrial-derived peptide MOTS-c: a player in exceptional longevity?" Aging Cell, 2015. (Hypothesis paper on a mitochondrial DNA variant; no treatment data.) View study

"MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity" (MOTS-MET). ClinicalTrials.gov identifier NCT07505745. Randomized, placebo-controlled Phase 2a; recruiting as of September 2026; estimated primary completion February 2027. View study

MOTS-c

PeRx MOTS-c is prescribed by a licensed provider after a health screening and compounded at a US-based 503A pharmacy at 2 mg/mL in a 5 mL vial, tested for potency and sterility. It ships fully reconstituted and ready to use, with no powder to mix and no concentration to work out.

$229 for a one-month supply. It suits people who train, track, and want a metabolic experiment with a written baseline rather than a visible transformation.

Ready-to-use vial at 2 mg/mL.

Shop Now

How to Run Your Own Before and After

You cannot audit a forum post, but you can run a clean experiment on yourself, and MOTS-c suits one because its plausible effects are the measurable kind. The setup takes one baseline week before the first dose and ten minutes a week after that.

Labs, through your regular physician. A fasting glucose and an HbA1c before you start; the fasting glucose again around week four and the HbA1c at the end of the cycle. Do not order a plasma MOTS-c level; it is not a validated marker of anything an injection does.

One benchmark workout, every two weeks. Something you can do identically: a timed 5K, a fixed circuit, a set at a fixed load to failure. Same time of day, same warm-up, similar sleep the night before. This single line is the closest a normal person gets to the treadmill test in the mouse studies, and it is far more sensitive than how you feel.

Tape monthly, and a morning rating daily. Waist at the navel, same time of morning, monthly rather than weekly, because body measurements are noisy; a baseline DEXA repeated at the end of the cycle is the gold standard if you want one. Photos only in identical conditions, monthly at most. Then energy from 1 to 10 at the same time each day. Capture at least one baseline week, because once you feel better you will genuinely forget how you felt before.

Then wait the full cycle. Judging a 12-week metabolic experiment at week three is the most common way people talk themselves into or out of a peptide; the onset timeline guide Read nextHow Long Do Peptides Take to Work?Anywhere from the same evening to several months, depending on which peptide and which change you are watching for. PT-141 is dosed for a same-day window while GHK-Cu skin remodeling is a months-long project, and most peptides land somewhere between. This guide maps the typically reported onset windows by peptide family, explains what tends to change first for each goal, and covers why feeling nothing early is often normal rather than a sign of failure.Read article explains why each class runs on its own clock. Athletes have one more line to read first: MOTS-c is prohibited at all times under WADA section S4.4.1 as an AMPK activator, and USADA considers a therapeutic use exemption highly unlikely. A drug-tested athlete cannot run this experiment.

Can You Lose Weight With MOTS-c?

This is the question behind most searches for MOTS-c results, so it deserves a plain answer: not the way the photos suggest. Treated mice on a high-fat diet gained less fat while eating the same amount, a fuel-use shift rather than an appetite effect, and the analog trial produced only a non-significant weight trend in four weeks. MOTS-c does not suppress appetite and is not a weight-loss therapy; the fat-loss peptide guide Read nextBest Peptides for Fat Loss: Ranked by EvidenceMost rankings of fat-loss peptides are marketing dressed up as science. This one is built the way a prescribing clinic actually thinks: four tiers, ordered by the strength of the human evidence, with an honest section on the peptides that are not worth your money at all.Read article maps what does have human outcome data. Which brings up the photos. A large share of dramatic MOTS-c images online come from people stacking it with a GLP-1 medication, often named in the same post, and the weight change belongs to the GLP-1. Compounded semaglutide and tirzepatide are a different class, and they are not the FDA-approved brands whose trial results get quoted alongside them; what compounded semaglutide is Read nextWhat Is Compounded Semaglutide? Is It Safe?Compounded semaglutide is the same active molecule as Ozempic and Wegovy, prepared by a licensed pharmacy for one named patient instead of manufactured under an FDA approval. That one sentence carries a lot of legal weight. This page unpacks it: what compounding is, how the compounded product differs from the brands, what changed between 2022 and 2026, and what a legitimate prescription looks like from inside a clinic that writes them.Read article explains that distinction, and the MOTS-c and semaglutide guide Read nextMOTS-c and Semaglutide: Can You Combine Them?Ask this question online and you get two kinds of answers. Retail sites say yes and quote fat-loss percentages that do not exist anywhere in the literature. Cautious sites say nothing has been studied and stop there. Both halves are doing part of the job. This page does the whole thing: what is actually known, including the analog trial almost nobody mentions, and how a prescribing clinic thinks about the combination in practice.Read article covers what each contributes when both are prescribed.

When You Feel Nothing

Suppose you tracked honestly, the cycle ended, and neither the benchmark workout nor the labs moved. That is real information with a short list of explanations. Start with the trial itself: missed injections, no training stimulus for the peptide to act on, or wrecked sleep all blunt whatever effect exists; in a sedentary week there is nothing for the signal to amplify. Next, the dose question the benefits guide Read nextMOTS-c Benefits: What the Evidence SupportsAlmost every benefit attributed to MOTS-c traces back to a mouse, a cell culture, or a blood test measuring the peptide your own mitochondria already make. This page grades each claim by what was measured, what it was measured in, and whether anyone has given injected MOTS-c to a person and looked.Read article raises: nobody has established how an injected dose compares with what your mitochondria release, so a null result at one dose is not a verdict on the molecule. Then the honest possibility: MOTS-c may not do much for you. Bring your data to your provider; sometimes the answer is a different protocol, sometimes a peptide with more human evidence, sometimes the conclusion that this pathway is not your bottleneck. The what to do when a peptide does not seem to work guide Read nextPeptide Not Working? Timelines, Causes and Next StepsMost peptide marketing implies a guaranteed outcome. The honest answer is that no peptide works for everyone, and the question worth asking before you start is what happens if it does not work for you. Here is what "not working" actually looks like, the realistic timelines so you do not quit too early, the real reasons a peptide underdelivers, and the next steps when one is not earning its place.Read article walks through those steps. The answer is never quietly raising your own dose.

Red Flags in MOTS-c Results Content

A confident week-by-week schedule with no study behind it. "Measurable drops in visceral fat by week six" is a sentence no MOTS-c trial has ever produced. A page stating it as fact either invented it or copied it from a page that did. The honest form of every timeline claim for this peptide includes the word "report."

Mouse results quoted as human results. Improved running capacity, less fat gain on a high-fat diet, reversed age-related decline: all real findings, all in mice. A page that drops the species is dropping the most important word in the sentence, and "exercise in a vial" is the same move; exercise produces hundreds of adaptations no single molecule reproduces.

No prescriber in sight. MOTS-c is a prescription peptide, and the FDA’s 2026 review worried about the vial as much as the molecule. A site posting results imagery without a licensed provider and a pharmacy behind it is selling unregulated product; the regulatory picture is in is MOTS-c FDA approved Read nextIs MOTS-c FDA Approved? Mitochondrial Peptide StatusNo. MOTS-C was only discovered in 2015. It is the newest peptide in clinical use and the first peptide ever found to be encoded by mitochondrial DNA rather than nuclear DNA. That discovery, from Changhan David Lee's lab at USC, upended decades of assumptions about where bioactive peptides come from. Here is what we know so far.Read article .

MOTS-c Before and After: Common Questions